RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.